Rutika Mehta, Academic GI medical oncologist at Weill Cornell Medicine, shared a post on X about a recent article she and her colleagues co-authored, adding:
“Fruits of labor. Our IIT with ramucirumab and FTD/TPI in gastric cancers at Moffitt Cancer Center is now published.
Combination was safe and yielded 6-month OS 57% and DCR 94%.”
Title: A Phase II study of Trifluridine/Tipiracil (FTD/TPI) in Combination with Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction adenocarcinomas
Authors: Dae Won Kim, Richard D Kim, Maria Martinez Jimenez, Youngchul Kim, Rutika Mehta
Read the Full Article on The Oncologist
More posts about Gastric Cancers